Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.

Kenmotsu H, Niho S, Tsuboi M, Wakabayashi M, Ishii G, Asahina H, Watanabe K, Kiyoshima M, Iwata T, Nakamura Y, Nakahara Y, Chen-Yoshikawa TF, Nishino K, Nishio W, Yokoyama T, Mitome N, Asamura H, Ohe Y, Watanabe SI

Open source

DOI: 10.1016/j.lungcan.2026.109386
Published: 2026 Jun
Container: Lung cancer (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2026.109386,
  title = {Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.},
  author = {Kenmotsu H and Niho S and Tsuboi M and Wakabayashi M and Ishii G and Asahina H and Watanabe K and Kiyoshima M and Iwata T and Nakamura Y and Nakahara Y and Chen-Yoshikawa TF and Nishino K and Nishio W and Yokoyama T and Mitome N and Asamura H and Ohe Y and Watanabe SI},
  year = {2026},
  journal = {Lung cancer (Amsterdam, Netherlands)},
  doi = {10.1016/j.lungcan.2026.109386},
  url = {https://doi.org/10.1016/j.lungcan.2026.109386}
}

RIS

TY  - JOUR
TI  - Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.
AU  - Kenmotsu H
AU  - Niho S
AU  - Tsuboi M
AU  - Wakabayashi M
AU  - Ishii G
AU  - Asahina H
AU  - Watanabe K
AU  - Kiyoshima M
AU  - Iwata T
AU  - Nakamura Y
AU  - Nakahara Y
AU  - Chen-Yoshikawa TF
AU  - Nishino K
AU  - Nishio W
AU  - Yokoyama T
AU  - Mitome N
AU  - Asamura H
AU  - Ohe Y
AU  - Watanabe SI
PY  - 2026
JO  - Lung cancer (Amsterdam, Netherlands)
DO  - 10.1016/j.lungcan.2026.109386
UR  - https://doi.org/10.1016/j.lungcan.2026.109386
ER  -

APA

H, K., S, N., M, T., M, W., G, I., H, A., K, W., M, K., T, I., Y, N., Y, N., TF, C., K, N., W, N., T, Y., N, M., H, A., Y, O., & SI, W. (2026). Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2026.109386

Source records

pubmed · retrieved 2026-09-26T08:53:21.088Z